Bioprocess development and scale-up require many costly physical experiments and can fail when conditions change across bioreactor scales.
R&D Focus
AI bioprocess simulation, digital twins, cell-culture optimization and scale-up.
Innovative Solution
Ark’s no-code software creates calibrated virtual bioreactors, runs thousands of in-silico experiments and ranks process recipes before physical testing.
Solution Effectiveness
The company states simulations can run 1,000 times faster than physical experiments and can explore tens of thousands of process variations; these are company-reported capabilities.
Investment Funding
Last Funding Stage
Venture - Series Unknown
Total Funding Amount
16.68M
Last Funding Amount
8.18M
Last Funding Date
24-05-2024
Lead Investors
Primary Venture Partners, HCVC, Rob Hayes, Kevin Carter, Natalie Portman
People
Founders
Yossi Quint
About
With an intelligent bioprocess platform, Ark helps today’s innovators make better decisions and accelerate development timelines dramatically — to bring transformational science to those who need it most.
Products
Product
Ark bioprocess simulation platform and Bioprocess AI Assistant.
